Orano Med

Orano Med (previously known as AREVA Med) is a biotechnology company specializing in nuclear medicine to develop new treatments against cancer. Its approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. The company develops therapies against cancer using the properties of lead-212 (212Pb), a rare alpha-emitting radioisotope.